Generic Exclusivity Suit Says US FDA Can’t Deny Prize If It Asks For Extra Data

Amneal’s Namenda XR lawsuit asserts FDA’s determination that it forfeited 180-day marketing exclusivity on memantine extended-release generics ignores delays resulting from agency’s unexpected request for data from commercial-size lots.

A lawsuit over generic versions of Allergan PLC’s Alzheimer’s drug Namenda XR (memantine extended-release) is challenging how FDA determines whether an abbreviated new drug application (ANDA) sponsor has forfeited generic marketing exclusivity.

In a Jan. 27 complaint, Amneal Pharmaceuticals LLC asks the US District Court for the District of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics